Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Buggisch

Showing results (1-10 of 110) with videos related to

Pageof 11
Sort By:
Journal of Hepatology|May 15, 2018
Reply to: "Real-world data on antiviral treatments for hepatitis C virus infections: Can we define intention to treat or per protocol analyses?"Peter Buggisch, Stefan Zeuzem
MMW Fortschritte Der Medizin|May 15, 2025
[Treatment strategies for hepatitis B, C and D]Jörg Petersen, Peter Buggisch
Arzneimittel-Forschung|August 6, 2005
Bioavailability of oral iron drugs as judged by a 59Fe-whole-body counting technique in patients with iron deficiency anaemia. Therapeutic efficacy of iron(II)-glycine sulfatePeter Nielsen, Rosemarie Kongi, Peter Buggisch, et al.
British Journal of Haematology|November 25, 2003
Effective treatment of hereditary haemochromatosis with desferrioxamine in selected casesPeter Nielsen, Roland Fischer, Peter Buggisch, et al.
Antiviral Therapy|September 13, 2006
Temporary HBV resolution in an HIV-coinfected patient during HBV-directed combination therapy followed by relapse of HBVKarsten Wursthorn, Peter Buggisch, Marc Lutgehetmann, et al.
European Journal of Gastroenterology & Hepatology|November 19, 2003
First-line therapy with daily versus thrice-weekly interferon alfa-2b plus ribavirin for chronic hepatitis CMarkus Reiser, Peter Buggisch, Johannes Grossmann, et al.
Hepatology (Baltimore, Md.)|May 4, 2004
Does noninvasive staging of fibrosis challenge liver biopsy as a gold standard in chronic hepatitis C?Thomas Berg, Christoph Sarrazin, Holger Hinrichsen, et al.
Plos One|April 5, 2019
Real-world effectiveness and safety of sofosbuvir/velpatasvir and ledipasvir/sofosbuvir hepatitis C treatment in a single centre in GermanyPeter Buggisch, Karsten Wursthorn, Albrecht Stoehr, et al.
Hepatology (Baltimore, Md.)|April 12, 2011
"Real-Life" comparison of pegylated-interferon 2a versus 2b combination therapy of chronic hepatitis C virusJulian Schulze Zur Wiesch, Neele Pudelski, Lena Hoepner, et al.
Zeitschrift Fur Gastroenterologie|April 22, 2026
[Hyperlipasemia following therapy with direct antiviral drugs in patients with chronic hepatitis C virus infection - data from the German Hepatitis C Registry (DHC-R)]Bernd Heinrich, Peter Buggisch, Gerlinde Teuber, et al.
Pageof 11

Showing results (1-10 of 110) with videos related to

Sort By:
Pageof 11
Journal of Hepatology|May 15, 2018
Reply to: "Real-world data on antiviral treatments for hepatitis C virus infections: Can we define intention to treat or per protocol analyses?"Peter Buggisch, Stefan Zeuzem
MMW Fortschritte Der Medizin|May 15, 2025
[Treatment strategies for hepatitis B, C and D]Jörg Petersen, Peter Buggisch
Arzneimittel-Forschung|August 6, 2005
Bioavailability of oral iron drugs as judged by a 59Fe-whole-body counting technique in patients with iron deficiency anaemia. Therapeutic efficacy of iron(II)-glycine sulfatePeter Nielsen, Rosemarie Kongi, Peter Buggisch, et al.
British Journal of Haematology|November 25, 2003
Effective treatment of hereditary haemochromatosis with desferrioxamine in selected casesPeter Nielsen, Roland Fischer, Peter Buggisch, et al.
Antiviral Therapy|September 13, 2006
Temporary HBV resolution in an HIV-coinfected patient during HBV-directed combination therapy followed by relapse of HBVKarsten Wursthorn, Peter Buggisch, Marc Lutgehetmann, et al.
European Journal of Gastroenterology & Hepatology|November 19, 2003
First-line therapy with daily versus thrice-weekly interferon alfa-2b plus ribavirin for chronic hepatitis CMarkus Reiser, Peter Buggisch, Johannes Grossmann, et al.
Hepatology (Baltimore, Md.)|May 4, 2004
Does noninvasive staging of fibrosis challenge liver biopsy as a gold standard in chronic hepatitis C?Thomas Berg, Christoph Sarrazin, Holger Hinrichsen, et al.
Plos One|April 5, 2019
Real-world effectiveness and safety of sofosbuvir/velpatasvir and ledipasvir/sofosbuvir hepatitis C treatment in a single centre in GermanyPeter Buggisch, Karsten Wursthorn, Albrecht Stoehr, et al.
Hepatology (Baltimore, Md.)|April 12, 2011
"Real-Life" comparison of pegylated-interferon 2a versus 2b combination therapy of chronic hepatitis C virusJulian Schulze Zur Wiesch, Neele Pudelski, Lena Hoepner, et al.
Zeitschrift Fur Gastroenterologie|April 22, 2026
[Hyperlipasemia following therapy with direct antiviral drugs in patients with chronic hepatitis C virus infection - data from the German Hepatitis C Registry (DHC-R)]Bernd Heinrich, Peter Buggisch, Gerlinde Teuber, et al.
Pageof 11